Intravesical combination chemotherapy with mitomycin C and doxorubicin for carcinoma in situ of the bladder

The Journal of Urology
I FukuiS Suzuki

Abstract

We treated 30 patients with carcinoma in situ of the bladder via intravesical combination chemotherapy. As an induction therapy 20 mg. mitomycin C on day 1 and 40 mg. doxorubicin on day 2 were instilled into the bladder once a week for 5 consecutive weeks. Patients who achieved complete response were assigned a maintenance instillation of mitomycin C alone every 2 to 4 weeks for 1 year. A total of 19 patients achieved complete response following an initial course of induction therapy and 2 partial responders to initial therapy also achieved complete response after repeated induction therapy, resulting in a 70 per cent over-all complete response rate. Toxicity was considerable with moderate to severe bladder irritation occurring in 20 patients but it was tolerable in the majority. Of 21 complete responses 13 remained free of disease for 6 to 43 months (average of 23 months), 5 had recurrent carcinoma in situ and 1 had invasive urethral cancer. In contrast, of 9 nonresponders 2 and 1 had invasive cancer of the bladder and ureter, respectively.

References

Jan 1, 1987·Cancer Chemotherapy and Pharmacology·I FukuiS Ikegami
Oct 1, 1987·The Journal of Urology·G R ProutJ J Daly
Feb 1, 1970·The Journal of Urology·D C UtzG M Farrow
Jan 1, 1984·Scandinavian Journal of Urology and Nephrology·A EkW Månsson
Sep 16, 1961·Lancet·H C JONES, J SWINNEY
Oct 1, 1963·Cancer·N G VOUTSA, M R MELAMED

❮ Previous
Next ❯

Citations

Jun 6, 2009·Expert Review of Anticancer Therapy·Frances M Martin, Ashish M Kamat
Oct 6, 2006·World Journal of Urology·Michael A O'Donnell, Andreas Boehle
Oct 31, 2001·International Journal of Urology : Official Journal of the Japanese Urological Association·H SekineI Fukui

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bladder Carcinoma In Situ

Bladder Carcinoma In Situ is a superficial bladder cancer that occurs on the surface layer of the bladder. Discover the latest research on this precancerous condition in this feed.